NCT07008846View on ClinicalTrials.gov

Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

May 10, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Moderate to Severe Rheumatoid Arthritis
Interventions
DRUG

To see the efficacy of Upadacitinib, Methotrexate versus Tofacitinib, Methotrexate in moderate to severe Rheumatoid arthritis

This intervention is open label. Both patient and investigator will know about the intervention. Participants are allocated according to block randomization. Total two groups with each contain 48 patients. One group will be given Tofacitinib, Methotrexate and another group will be given Upadacitinib, Methotrexate

Trial Locations (1)

1000

Bangabandhu Sheikh Mujib Medical University, Dhaka

All Listed Sponsors
lead

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

OTHER

NCT07008846 - Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter